M&A Deal Summary |
|
|---|---|
| Date | 2009-04-01 |
| Target | Cellegy Pharmaceuticals |
| Sector | Healthcare Services |
| Buyer(s) | DMK Pharmaceuticals |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2006 |
| Sector | Life Science |
| Employees | 11 |
| Revenue | 2M USD (2021) |
DMK Pharmaceuticals is a specialty biopharmaceutical company that provides high quality, low-cost solutions for patients, physicians, and healthcare organizations in the multi-billion dollar therapeutic areas of respiratory disease and allergies. DMK Pharmaceuticals was incorporated in 2006 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 1 of 3 |
| Year: 2009 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-06 |
3M Co. - Taper Dry Powder Inhaler
United States 3M Co. - Taper Dry Powder Inhaler is a developer of treatment for asthma and chronic obstructive pulmonary disease (COPD). |
Buy | - |
